[{"data":1,"prerenderedAt":145},["ShallowReactive",2],{"drug-ibuprofen-lysine":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":21,"regimens":35,"contraindications":79,"warnings":89,"renal":90,"monitoring":91,"interactions":92,"review":93,"examples":96,"atc":109,"iran":111,"links":118,"populations":130,"usApproval":140},"ibuprofen-lysine",1,{"fa":7,"en":8},"ایبوپروفن لیزین وریدی (نوزاد)","Ibuprofen lysine IV (neonatal)","cardiovascular",{"fa":11,"en":12},"NSAID برای بستن PDA","NSAID for PDA closure",[14],{"name":15,"market":16},"NeoProfen","US",[18,19,20],"neoprofen","نئوپروفن","ایبوپروفن وریدی نوزاد",[22],{"id":23,"form":24,"route":25,"label":26,"concentration":27,"markets":30,"refs":31},"vial-10","injection","iv","10 mg\u002FmL (20 mg\u002F2 mL) vial",{"amount":28,"unit":29,"perVolumeMl":5},10,"mg",[16],[32],{"source":33,"section":34},"fda-neoprofen","3",[36,60],{"id":37,"disease":38,"label":39,"population":42,"type":45,"unit":29,"dose":46,"refs":47,"durationDays":50,"notes":51},"first","pda",{"fa":40,"en":41},"PDA نوزاد نارس — دوز اول ۱۰ mg\u002Fkg وریدی","Preterm PDA — first dose 10 mg\u002Fkg IV",{"maxAge":43},{"value":5,"unit":44},"year","weightBased",{"perKgPerDay":28,"dividedDoses":5},[48],{"source":33,"section":49},"2.1",{"min":5,"max":5},[52],{"text":53,"refs":56},{"fa":54,"en":55},"دوزها بر اساس وزن تولد. اگر هنگام دوز دوم یا سوم آنوری یا الیگوری (زیر ۰٫۶ mL\u002Fkg\u002Fساعت) بود، تا طبیعی شدن کلیه داده نشود. رقیق و در ۱۵ دقیقه انفوزیون.","Doses by birth weight. Withhold the 2nd\u002F3rd dose if anuria or oliguria (\u003C0.6 mL\u002Fkg\u002Fh) until renal function normalises. Dilute and infuse over 15 min.",[57,58],{"source":33,"section":49},{"source":33,"section":59},"2.2",{"id":61,"disease":38,"label":62,"population":65,"type":45,"unit":29,"dose":67,"refs":69,"durationDays":71,"notes":73},"next",{"fa":63,"en":64},"PDA — دوز دوم و سوم ۵ mg\u002Fkg پس از ۲۴ و ۴۸ ساعت","PDA — 2nd and 3rd doses 5 mg\u002Fkg after 24 and 48 h",{"maxAge":66},{"value":5,"unit":44},{"perKgPerDay":68,"dividedDoses":5},5,[70],{"source":33,"section":49},{"min":72,"max":72},2,[74],{"text":75,"refs":76},{"fa":54,"en":55},[77,78],{"source":33,"section":49},{"source":33,"section":59},[80],{"id":81,"severity":82,"text":83,"refs":86},"ci","block",{"fa":84,"en":85},"عفونت درمان‌نشده؛ بیماری قلبی وابسته به PDA؛ خونریزی فعال (داخل جمجمه یا گوارش)؛ ترومبوسیتوپنی؛ اختلال انعقادی؛ NEC؛ اختلال قابل‌توجه کلیه.","Untreated infection; ductal-dependent congenital heart disease; active bleeding (intracranial or GI); thrombocytopenia; coagulation defects; NEC; significant renal impairment.",[87],{"source":33,"section":88},"4",[],[],[],[],{"status":94,"reviewer":95,"date":95},"unverified",null,[97,103],{"regimen":37,"formulation":23,"input":98,"expect":101},{"ageDays":99,"weightKg":100},3,1.5,{"perDose":102,"mlPerDose":100},15,{"regimen":61,"formulation":23,"input":104,"expect":106},{"ageDays":105,"weightKg":100},4,{"perDose":107,"mlPerDose":108},7.5,0.75,[110],"C01EB16",{"status":112,"refs":113},"not-found",[114],{"source":115,"section":116,"url":117},"darooyab-generic","search","https:\u002F\u002Fwww.darooyab.ir\u002FSearch?q=Ibuprofen%20lysine%20IV",[119,123,127],{"kind":120,"url":121,"label":122},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=021903","NDA021903",{"kind":124,"url":125,"label":126},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=6f5ede6f-b0b7-4fc8-969e-652f60ead047","FDA NeoProfen",{"kind":128,"url":129,"label":110},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=C01EB16",{"pediatric":131},{"level":132,"text":133,"quote":136,"refs":137},"caution",{"fa":134,"en":135},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","Safety and effectiveness have only been established in premature infants.",[138],{"source":33,"section":139},"8.4",{"kind":141,"refs":142,"id":122},"NDA",[143],{"source":33,"section":144},"SPL approval \u002F marketing category",1792111456853]